REPLIMUNE GROUP, INC. Lease, Cost
REPLIMUNE GROUP, INC. (REPL) reported Lease, Cost of $1.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-08-14
- REPLIMUNE GROUP, INC. lease, cost for the quarter ending 2026-06-30 was $1.40M, a 0.99% decline year-over-year.
- REPLIMUNE GROUP, INC. lease, cost for the quarter ending 2026-03-31 was $1.41M, a 0.28% decline year-over-year.
- REPLIMUNE GROUP, INC. lease, cost for the quarter ending 2025-12-31 was $1.41M, a 0.49% decline year-over-year.
- REPLIMUNE GROUP, INC. lease, cost for the quarter ending 2025-09-30 was $1.42M, a 0.56% decline year-over-year.
- REPLIMUNE GROUP, INC. lease, cost for fiscal 2026 was $5.65M, a 0.49% decline from fiscal 2025.
- REPLIMUNE GROUP, INC. lease, cost for fiscal 2025 was $5.67M, a 0.67% decline from fiscal 2024.
- REPLIMUNE GROUP, INC. lease, cost for fiscal 2024 was $5.71M, a 1.24% increase from fiscal 2023.
- REPLIMUNE GROUP, INC. lease, cost for fiscal 2023 was $5.64M, a 0.19% decline from fiscal 2022.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40M 10-Q · filed 2026-08-14 | $2.81M derived: sum of 2 quarters · filed 2026-08-14 | $4.22M derived: sum of 3 quarters · filed 2026-08-14 | $5.63M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $2.82M derived: sum of 2 quarters · filed 2026-06-29 | $4.23M derived: sum of 3 quarters · filed 2026-06-29 | $5.65M 10-K · filed 2026-06-29 |
| 2025-12-31 | $1.41M 10-Q · filed 2026-02-03 | $2.83M derived: sum of 2 quarters · filed 2026-02-03 | $4.24M 10-Q · filed 2026-02-03 | $5.65M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-09-30 | $1.42M 10-Q · filed 2025-11-06 | $2.83M 10-Q · filed 2025-11-06 | $4.24M derived: sum of 3 quarters · filed 2026-08-14 | $5.66M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.42M 10-Q · filed 2026-08-14 | $2.83M derived: sum of 2 quarters · filed 2026-08-14 | $4.25M derived: sum of 3 quarters · filed 2026-08-14 | $5.67M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $2.83M derived: sum of 2 quarters · filed 2026-06-29 | $4.25M derived: sum of 3 quarters · filed 2026-06-29 | $5.67M 10-K · filed 2026-06-29 |
| 2024-12-31 | $1.42M 10-Q · filed 2026-02-03 | $2.84M derived: sum of 2 quarters · filed 2026-02-03 | $4.26M 10-Q · filed 2026-02-03 | $5.69M derived: sum of 4 quarters · filed 2026-02-03 |
| 2024-09-30 | $1.42M 10-Q · filed 2025-11-06 | $2.85M 10-Q · filed 2025-11-06 | $4.27M derived: sum of 3 quarters · filed 2025-11-06 | $5.70M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.42M 10-Q · filed 2025-08-07 | $2.85M derived: sum of 2 quarters · filed 2025-08-07 | $4.27M derived: sum of 3 quarters · filed 2025-08-07 | $5.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-22 | $2.85M derived: sum of 2 quarters · filed 2025-05-22 | $4.28M derived: sum of 3 quarters · filed 2025-05-22 | $5.71M 10-K · filed 2025-05-22 |
| 2023-12-31 | $1.43M 10-Q · filed 2025-02-12 | $2.86M derived: sum of 2 quarters · filed 2025-02-12 | $4.29M 10-Q · filed 2025-02-12 | $5.70M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-09-30 | $1.43M 10-Q · filed 2024-11-12 | $2.86M 10-Q · filed 2024-11-12 | $4.27M derived: sum of 3 quarters · filed 2024-11-12 | $5.68M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.43M 10-Q · filed 2024-08-08 | $2.84M derived: sum of 2 quarters · filed 2024-08-08 | $4.25M derived: sum of 3 quarters · filed 2024-08-08 | $5.66M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-16 | $2.82M derived: sum of 2 quarters · filed 2024-05-16 | $4.22M derived: sum of 3 quarters · filed 2024-05-16 | $5.64M 10-K · filed 2024-05-16 |
| 2022-12-31 | $1.41M 10-Q · filed 2024-02-08 | $2.82M derived: sum of 2 quarters · filed 2024-02-08 | $4.23M 10-Q · filed 2024-02-08 | $5.66M derived: sum of 4 quarters · filed 2024-02-08 |
| 2022-09-30 | $1.41M 10-Q · filed 2023-11-07 | $2.83M 10-Q · filed 2023-11-07 | $4.25M derived: sum of 3 quarters · filed 2023-11-07 | $5.67M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.42M 10-Q · filed 2023-08-03 | $2.85M derived: sum of 2 quarters · filed 2023-08-03 | $4.26M derived: sum of 3 quarters · filed 2023-08-03 | $5.67M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-18 | $2.84M derived: sum of 2 quarters · filed 2023-05-18 | $4.25M derived: sum of 3 quarters · filed 2023-05-18 | $5.65M 10-K · filed 2023-05-18 |
| 2021-12-31 | $1.41M 10-Q · filed 2023-02-09 | $2.82M derived: sum of 2 quarters · filed 2023-02-09 | $4.23M 10-Q · filed 2023-02-09 | $5.64M derived: sum of 4 quarters · filed 2023-02-09 |
| 2021-09-30 | $1.41M 10-Q · filed 2022-11-03 | $2.82M 10-Q · filed 2022-11-03 | $4.22M derived: sum of 3 quarters · filed 2022-11-03 | $5.63M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $1.41M 10-Q · filed 2022-08-04 | $2.82M derived: sum of 2 quarters · filed 2022-08-04 | $4.22M derived: sum of 3 quarters · filed 2022-08-04 | $5.63M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-05-19 | $2.81M derived: sum of 2 quarters · filed 2022-05-19 | $4.22M derived: sum of 3 quarters · filed 2022-05-19 | $5.62M 10-K · filed 2022-05-19 |
| 2020-12-31 | $1.41M 10-Q · filed 2022-02-03 | $2.81M derived: sum of 2 quarters · filed 2022-02-03 | $4.21M 10-Q · filed 2022-02-03 | $5.60M derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-09-30 | $1.41M 10-Q · filed 2021-11-04 | $2.80M 10-Q · filed 2021-11-04 | $4.20M derived: sum of 3 quarters · filed 2021-11-04 | $5.66M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.40M 10-Q · filed 2021-08-06 | $2.79M derived: sum of 2 quarters · filed 2021-08-06 | $4.25M derived: sum of 3 quarters · filed 2021-08-06 | $4.63M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-05-20 | $2.85M derived: sum of 2 quarters · filed 2021-05-20 | $3.23M derived: sum of 3 quarters · filed 2021-05-20 | $3.34M 10-K · filed 2021-05-20 |
| 2019-12-31 | $1.46M 10-Q · filed 2021-02-04 | $1.84M derived: sum of 2 quarters · filed 2021-02-04 | $1.95M 10-Q · filed 2021-02-04 | |
| 2019-09-30 | $378.00K 10-Q · filed 2020-11-05 | $492.00K 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | $114.00K 10-Q · filed 2020-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |